ACOR Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (11 apr 2024 @ 22:00):
Our systems believe the stock currently is overvalued by -7.37% compare to its pairs and should correct downwards.

Stats
Dagens volum	321 668
Gjennomsnittsvolum	125 680
Markedsverdi	821 028
EPS	$-22.06 ( Q1 \| 2024-05-14 )
Neste inntjeningsdato	( $0 ) 2024-08-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.00325 (Sector) 42.63 (Industry) 0
ATR14	$0.0120 (1.96%)

ACOR -24.02%

ACRX 7.50%

ADMP 0.85%

ADMS 0.00%

AGRX 0.71%

AKAN -3.24%

ALIM -0.72%

AMPH -4.55%

AMYT 0.00%

ANIP -1.26%

AQST -6.73%

ASRT 0.40%

ATNX 0.00%

AVDL -2.17%

AYTU -1.37%

BFRI -0.89%

BGXX 8.21%

CLVR 0.00%

COLL 0.93%

CPIX -1.31%

CRDL -1.98%

CRON -1.72%

CYTH -3.40%

DCPH 0.00%

DERM -3.58%

DRRX 0.81%

DVAX -0.67%

EGRX -2.68%

EMBC -2.24%

EMBCV -9.33%

EOLS 0.88%

ESPR 7.64%

EVOK -4.54%

FLGC -1.96%

FLXN 0.00%

GHSI -1.68%

HCM 2.75%

HROW 0.48%

HUGE -3.81%

IMCC -4.13%

INCR 1.99%

IRWD 0.61%

ITCI -2.47%

IXHL 0.34%

JUPW 11.76%

KALA -2.97%

KIN 0.11%

KMDA -1.20%

LNTH -0.07%

NBIX 1.39%

NEPT 0.00%

NLTX 1.45%

OGI 0.97%

OPTN 1.91%

ORGO -2.68%

PAHC 1.97%

PCRX 0.45%

PETQ 0.82%

PLXP 0.00%

PPD 0.00%

PROC -0.32%

PRPH -2.63%

PTPI -1.20%

RDHL 1.67%

RDUS 0.33%

REPH -0.48%

RGC -5.03%

RMTI -3.41%

SCTL 0.92%

SCYX -3.75%

SIGA -1.52%

SISI -13.46%

SNDL 0.53%

SNOA 3.40%

SSIC -2.87%

SUPN -1.27%

SXTC 0.00%

THTX 0.30%

TKNO -10.22%

TLGT -13.85%

TLRY 1.46%

TXMD 6.41%

TYHT -3.90%

UPC 3.75%

VTRS -0.61%

ZYNE 2.36%

Insider Trading

Date	Person	Action	Amount	type
2023-06-22	Burns Thomas M.	Buy	2 400	Non-Employee Stock Option
2023-06-22	Burns Thomas M.	Buy	0
2023-06-22	Varian John	Buy	1 200	Non-Employee Stock Option
2023-06-22	Panem Sandra Phd	Buy	1 200	Non-Employee Stock Option
2023-06-22	Kelley John P	Buy	1 200	Non-Employee Stock Option

INSIDER POWER
99.52
Last 96 transactions
Buy: 1 532 806 \| Sell: 94 790

Korrelasjon (AI algo v.1.1b): Overvalued: -7.37% $0.658 paired level. (Algoen sporer endringene til de mest korrelerte aksjene i sanntid og gir umiddelbar oppdatering)

Volum Korrelasjon

Lang: -0.43 (neutral)

Kort: -0.79 (moderate negative)

Signal:(18.947) Neutral

Acorda Therapeutics Inc Korrelasjon

10 Mest positive korrelasjoner
EIGR	0.869

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Acorda Therapeutics Inc Korrelasjon - Valuta/Råvare

0.28
( neutral )

0.38
( neutral )

0.00
( neutral )

0.10
( neutral )

-0.35
( neutral )

-0.05
( neutral )

Acorda Therapeutics Inc Økonomi

Annual	2023
Omsetning:	$117.63M
Bruttogevinst:	$71.59M (60.86 %)
EPS:	$-203.59

FY	2023
Omsetning:	$117.63M
Bruttogevinst:	$71.59M (60.86 %)
EPS:	$-203.59

FY	2022
Omsetning:	$118.57M
Bruttogevinst:	$88.23M (74.42 %)
EPS:	$-66.90

FY	2021
Omsetning:	$129.07M
Bruttogevinst:	$88.28M (68.40 %)
EPS:	$-12.86

Financial Reports:

No articles found.

Acorda Therapeutics Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Acorda Therapeutics Inc

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.